



Introduction Patients with schizophrenia are likely to constitute a high-risk group of individuals with 
respect to prevalence of oral diseases and they require special attention. Factors like nature of psychiatric 
disorders, length of stay and oral-side effects of psychotropic medications have been noted as contribu-
tors to poor oral health among institutionalized chronic psychiatric patients.
Methods This cross-sectional study comprised 190 inpatients with schizophrenia at the Dr Laza Lazarevic 
Clinic for Mental Disorders in Belgrade, and 190 mentally healthy patients at the Clinic for Periodontology 
and Oral Medicine, School of Dental Medicine, University of Belgrade. A questionnaire was designed for 
the purpose of this research with the aim of recording information on demographic data (age and sex), 
unhealthy habits (tobacco smoking, alcohol consumption and drug abuse), and data about the existence 
of any oral symptom and/or sings related to oral soft tissue pathology. All participants were subjected 
to targeted clinical examinations.
Results All study group patients were receiving psychotropic medications (mean number 4.18 ± 1.14; 
from 1 to 7 medications). The study group patients had a total of 272 symptoms and 121 signs of oral 
disorders; which was almost four times higher for symptoms and even nine times higher for signs of oral 
disorders than in the control group.
Conclusion Schizophrenia as a mental disorder does not directly affect the condition of oral health of this 
group of psychiatric patients, but indirectly – reducing their motivation and awareness of the importance 
of oral health, which is particularly emphasized in hospital conditions.
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INTRODUCTION
People with mental disorders are a part of the 
community deserving special attention. This 
group is often neglected by dental profession-
als due to ignorance, fear, stigma, misconcep-
tions and negative attitudes. However, they are 
of even more concern because there is a loss 
of productivity due to their disability and an 
increased health care cost and burden to the 
government and society [1]. The majority of 
them who required long-term psychiatric care 
worldwide have schizophrenia diagnosed as 
their primary mental disorder [2]. The preva-
lence of schizophrenia is less than 1% in general 
population, without sex differences [3]. Treat-
ment of institutionalized residents, especially 
those with schizophrenia, takes up an impor-
tant part of the health care resource, compared 
to other psychiatric inpatients [4].
Having in mind oral health, hospitalized 
psychiatric patients are likely to constitute a 
high-risk group of individuals with respect to 
prevalence of oral diseases and they require 
special attention [5]. Factors like nature of 
psychiatric disorders, and oral-side effects of 
antipsychotic medications have been noted as 
contributors to poor oral health among insti-
tutionalized patients with schizophrenia [6]. In 
addition, unhealthy behaviors such as smoking 
cigarettes, alcohol consumption and drug abuse 
have been linked to psychiatric disorders [7].
Some studies that have been done on pa-
tients with schizophrenia focused on the assess-
ment of dental caries and periodontal disease 
[8, 9, 10]. On the other hand, no published 
studies have addressed the prevalence of oral 
symptoms and disorders among inpatients with 
schizophrenia, or the influence of mental disor-
ders on these conditions, although some studies 
recorded a high prevalence of oral symptoms 
and disorders, such as xerostomia, hypersaliva-
tion, recurrent oral ulcerations (RAS), burning 
mouth syndrome (BMS), tongue and lips dis-
orders, oral lichen planus (OLP) etc. in psy-
chiatric patients [11–14]. Therefore, the aim 
of this study was to assess the prevalence of 
symptoms and signs of oral disorders among 
inpatients with schizophrenia and to evaluate 
association of demographic, medical charac-
teristics and unhealthy behaviors in this group 
of psychiatric inpatients with the development 
of oral soft tissue pathology.
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METHODS
This study was conducted as an observational cross-sec-
tional study, in accordance with the Declaration of Helsinki 
and it was approved by the Ethics Committee of the Dr Laza 
Lazarevic Clinic for Mental Disorders in Belgrade, Serbia 
(No. 7221), and the Faculty of Dental Medicine, Univer-
sity of Belgrade, Belgrade, Serbia (No. 36/10). The study is 
reported according to the Strengthening the Reporting of 
Observational Studies in Epidemiology (STROBE) state-
ment for improving the quality of observational studies [15].
Each subject participated voluntarily in the study and 
was informed, through a special brochure regarding the 
type of research, data collection procedure, and other as-
pects of the study. Written consent was obtained from all 
subjects or their legal representatives to use personal data 
for research purposes. The study enrolled two groups of 
patients. The study group compromised 190 randomly se-
lected patients with schizophrenia, hospitalized at the Dr. 
Laza Lazarevic Clinic for Mental Disorders in Belgrade, 
Serbia. The inclusion criteria for entering the study were 
that the patient was hospitalized, older than 18 years and 
diagnosed with schizophrenia (according to the 10. Revi-
sion of the International Classification of Diseases) two 
years prior to the study. Medical data for the study group 
patients (duration of psychiatric disease, number of hospi-
talizations, number and type of psychotropic medications) 
were taken from medical records. The exclusion criteria 
were a primary diagnosis of other mental disorder, hospi-
talized patients diagnosed with schizophrenia in the period 
shorter than two years from the time of the survey, the 
simultaneous presence of systematic diseases (e.g. nutri-
tional deficiency, cardiovascular, respiratory, metabolic, 
endocrinal disorders), medications for such systematic 
diseases, and inability to communicate or the refusal to 
cooperate. The control group also comprised 190 healthy 
subjects suffering from aggressive periodontitis, without 
any psychiatric or somatic illness, who were consecutively 
recruited from the pool of patients at the Clinic for Peri-
odontology and Oral Medicine, Faculty of Dental Medi-
cine, University in Belgrade, Serbia [16]. Participants of the 
control did not use any medications that could affect oral 
health [17]. Groups were age- and sex- matched.
A questionnaire was designed for the purpose of this 
research with the aim of recording information on de-
mographic data (age and sex), unhealthy habits (tobacco 
smoking, alcohol consumption and drug abuse), and data 
about the existence of any oral symptom and/or sings re-
lated to oral soft tissue pathology.
All participants were subjected to targeted clinical ex-
aminations in the dental office at the Dr Laza Lazarevic 
Clinic for Mental Disorders in Belgrade, Serbia (patients 
of the study group), and the Department of Periodontology 
and Oral Medicine, Faculty of Dental Medicine, Univer-
sity in Belgrade, Serbia (patients of the control group), 
according to criteria recommended by the World Health 
Organization [18]. The examination was performed in the 
following sequence: labial mucosa and labial sulci (upper 
and lower), labial part of the commissures and buccal mu-
cosa (right and left), tongue (dorsal and ventral surfaces, 
margins), floor of the mouth, hard and soft palate and 
alveolar ridges/gingiva (upper and lower). During clinical 
examination, the following elements of the lesion were ana-
lyzed: anatomical location, extension; possible etiological 
or related factors were also recorded [19].
All collected data were organized and evaluated using 
dedicated software (SPSS 17.0 Inc., Chicago, IL, USA) and 
were analyzed by descriptive statistical parameters, methods 
for testing the difference of numerical data and regression 
models. Descriptive statistical methods were represented by 
measures of central tendency (mean and median), measures 
of variability (standard deviation and variation interval) and 
were expressed in percentages. The methods for testing the 
difference of numerical data (age) were represented by the 
t-test of independent groups. For testing data of different 
categories (sex, medications, unhealthy habits), χ2 test was 
used. Level of significance was set at p < 0.05.
RESULTS
The study group consisted of 190 hospitalized patients with 
schizophrenia (95 males and 95 females) aged 19–67 years, 
with mean age of 43.59 ± 11.96 years. Most respondents 
(32.1%) were in age group over 50. The control group also 
consisted of 190 mentally healthy subjects (95 males and 
95 females) aged 19–72 years, with mean age 43.20 ± 11.89 
years. Most respondents in control group (30%) were in 
age group between 41–50. The groups thus where compa-
rable in terms of age (p = 0.747 for t-test of independent 
groups) and sex (p = 1.000 for Pearson χ2-test). 
Distributions of unhealthy habits in both groups are 
shown in Table 1. In the study group most of the patients 
pleaded that they consume alcoholic beverages, in con-
trast to the control group who have often declared not to 
consume alcoholic beverages. Also, most of study group 
patients said that they sometimes enjoy drugs, unlike men-
tally healthy individuals who, in almost all cases, stated that 
they do not enjoy them. Among the patients of the study 
group, almost 75% of them smoked cigarettes; unlikely, in 
the control group patients there was less than half smokers. 
A statistically significant difference between the two groups 
of participants was observed in all three observed variables 
in terms of practicing bad habits for oral health (Table 1).





























*statistically significant;  
aPearson χ2-test 
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In the study group, schizophrenia lasted 14.31 ± 9.19 
years on average (2–45 years). Most of patients (43.2%) 
have schizophrenia 11–20 years. The average number of 
hospitalizations per participant was 8.48 ± 5.71 (from one 
to 30). Sixty-eight patients with schizophrenia had less 
than ten hospitalizations, during the disease.
All study group patients were receiving psychotropic 
medications (mean number 4.18 ± 1.14; 1–7 medications) 
and in the greatest number – antipsychotics (mean number 
1.64 ± 0.66; 1–3) (Table 2). In addition to antipsychotic 
medications, patients of the study group received other 
medications, too (Table 2). Almost 71% of inpatients with 
schizophrenia received mood stabilizers, 84.2% of them 
anxiolytics, 33.2% hypnotics, 7.9% antidepressants and 
57.9% of them antiparkinsonics.
Based on the patients’ subjective symptoms and clinical 
examination of the oral cavity, in both groups were noted 
some oral soft tissue diseases (Table 3). Almost half of the 
study group patients, and over 65% of the control group 
patients were free of any oral soft tissue pathology. The 
subjects of the study group had a total of 272 symptoms 
and 121 signs of oral disorders; which was almost four 
times higher for symptoms and even nine times higher 
for signs of oral disorders than in the control group. In 
the study group an average number of oral symptoms per 
patient were 1.26 ± 1.20 (range 0–5) and for signs of oral 
disorders 0.91 ± 1.21 (range 0–4), despite of respondents 
in the control group, where an average number of oral 
symptoms per patient were 0.29 ± 0.52 (range 0–2) and 
oral disorders 0.12 ± 0.35 (range 0–2). Distribution of the 
symptoms and signs of oral disorders in both groups of 
patients is shown in Table 3.
Univariate logistic regression showed that only on BMS 
statistical significance had duration of mental disorder and 
smoking cigarettes (Table 4). Similar to that, multivariate 
logistic regression showed a statistical significance of BMS 
among inpatients with schizophrenia in terms of mental 
disorder duration and smoking cigarettes (Table 4).
Table 2. Psychotropic medications of patients in study group
Psychotropic medications Obtained values





























Table 3. Distribution of soft tissue pathology in both groups 







































Presence of oral signs:
Lips disorders
Tongue disorders


















*Statistically significant;  
aPearson χ2 test




Sex Age Duration of disease
Number of 
hospitalizations Antipsychotics Alcohol Narcotics Smoking 
Burning mouth syndrome
a0.362 a0.620 a0.028* a0.138 a0.655 a0.174 a0.180 a0.034*
/ / b0.012* / / / / b0.005*
Facial pain a0.034* a0.904 a0.279 a0.486 a0.863 a0.876 a0.378 a0.730
Hypersalivation a0.203 a0.670 a0.733 a0.290 a0.211 a0.519 a0.293 a0.829
Xerostomia a0.405 a0.565 a0.983 a0.205 a0.308 a0.705 a0.321 a0.643
Halitosis a0.129 a0.395 a0.963 a0.209 a0.895 a0.133 a0.254 a0.743
Gustatory sense dysfunction a0.924 a0.692 a0.297 a0.523 a0.994 a0.502 a0.419 a0.568
Swallowing difficulties a0.931 a0.406 a0.468 a0.988 a0.793 a0.539 a0.908 a0.353
Lips disorders a0.890 a0.943 a0.959 a0.186 a0.641 a0.632 a0.129 a0.475
Tongue disorders a0.008* a0.518 a0.132 a0.340 a0.864 a0.928 a0.970 a0.463
Soft and hard palate 
disorders
a0.771 a0.465 a0.320 a0.141 a0.743 a0.227 a0.793 a0.521
Oral mucosa disorders a0.293 a0.727 a0.874 a0.641 a0.217 a0.527 a0.758 a0.534
*Statistical significance;  
aunivariate logistic regression;  
bmultivariate logistic regression
DOI: https://doi.org/10.2298/SARH190311042D
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DISCUSSION
Based on anamnesis’ data and clinical examination of 
oral soft tissues, a statistically significant difference was 
found between inpatients with schizophrenia and mentally 
healthy patients in the presence of symptoms and signs of 
oral soft tissue diseases. Most commonly reported diseases 
were: xerostomia (43.2%), tongue illness (23.7%) and signs 
of buccal mucosa diseases (22.1%), as opposed to mentally 
healthy patients with the majority of cases registered with 
halitosis (18.9%). Xerostomia or “dry mouth” was the most 
common oral symptom that the inpatients with schizo-
phrenia complained, which corresponds to the results of 
some previous studies [14, 19]. These results should not 
be surprising because it is known that xerostomia and hy-
posalivation may be the consequence of the application of 
some psychotropic medications including: first generation 
antipsychotics, antiparkinsonics, antidepressants, as well 
as anxiolytics, which are often applied to inpatients with 
schizophrenia in our study [19–23]. However, in a num-
ber of previous studies, xerostomia has been registered 
at significantly lower percentages of patients than in our 
research; Dangore-Khasbage et al. [24] registered xerosto-
mia only in 13% of patients, Ujaoney et al. [25] in 22% of 
patients, while Morales-Chavez et al. [11] had xerostomia 
in only 9.23% of psychiatric patients. This can be explained 
by the fact that the researches concerned oral health of 
psychiatric patients (not only patients with schizophrenia), 
as well as that the patients in our study were treated with a 
greater number (1–3) of antipsychotics. Common habits 
such as smoking and alcohol consumption can cause some 
oral dryness [17]. The drugs most commonly implicated 
include antidepressants, antipsychotics, benzodiazepines, 
hypnotics, opioids, and substance abuse [17].
Most of inpatients with schizophrenia in this study had 
coated (n = 25) and black tongue (n = 12). Similar find-
ings were also obtained in previous studies: Znegin et al. 
[14] found coated tongue in 8% of patients, while Bertaud-
Gounot et al. [26] in 6.8% of patients. Coated tongue is a 
common oral-medical problem, due to accumulation of epi-
thelial cells, residues of food and microbial debris [27]. It is 
well known that the coated tongue is occurring in a person 
with xerostomia and those who do not maintain or irregu-
larly maintain oral hygiene [27]. Black tongue is a patho-
logical change that also occurs in people who have poor 
oral hygiene, who smoke, have xerostomia, and consume 
soft and non-abrasive food [27]. In our research most of the 
inpatients with schizophrenia said they smoked (74.7%). 
In addition, 22.1% examinees of the study group had 
some disease of oral mucosa, and the most common find-
ing of RAS (n = 13) and OLP (n = 11) was consistent with 
the results of other investigators. Dangore-Khasbage et 
al. [24] reported RAS at 16% and OLP at 2% of patients; 
Bertaud-Gounot et al. [27] reported RAS in 12.4% of 
patients; Kossioni et al. [19] registered RAS in 3.6% of 
psychiatric patients, while Lai et al. [28] shown that olan-
zapine, quetiapine and sulpiride posed a higher risk of oral 
ulcerations among psychiatric patients, compared to the 
other antipsychotics. Also, it is known that RAS and OLP 
have psychosomatic support, highlighting the importance 
of anxiety, stress and depression in the development of 
these oral diseases. Cerqueira et al. [29] in their research 
indicate that psychological disorders (in particular anxi-
ety and stress) have a high correlation with symptoms of 
OLP. Similar to that, Karthikeyan et al. [30] in their study 
indicate that stress can be a significant etiologic co-factor 
in OLP and RAS, which is interesting information that 
should be proven.
CONCLUSION
Based on the obtained risk factors for oral soft tissues 
diseases of schizophrenia inpatients, it can be said that 
schizophrenia as a mental disorder indirectly affect the 
condition of oral health of this group of psychiatric pa-
tients, by reducing their motivation and awareness of the 
importance of oral health, which is particularly empha-
sized in hospital conditions. Also, this research suggest 
that oral care of patients with schizophrenia must include 
periodic monitoring of dental and soft tissues, and that 
greater coordination between specialists of psychiatry and 
dentists may better serve the need of this neglect group of 
psychiatric patients. 
Conflict of interest: None declared.
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САЖЕТАК
Увод Хоспитализовани болесници са схизофренијом могу 
да представљају високо ризичну групу особа са аспекта пре-
валенције оралних обољења, те захтевају посебну пажњу. 
Фактори попут природе психијатријске болести, дужине 
хоспитализације и нежељених ефеката психотропних меди-
камената утичу на лоше оралнo здравље хоспитализованих 
хроничних психијатријских болесника.
Методе Ова студија пресека обухватила је 190 болесника 
са схизофренијом хоспитализованих у Клиници за пси-
хијатријске болести „Др Лаза Лазаревић“ у Београду и 190 
ментално здравих болесника Клинике за парадонтологију 
и оралну медицину Стоматолошког факултета Универзитета 
у Београду. У сврху овог истраживања дизајниран је упит-
ник са циљем бележења демографских података (старост и 
пол), лоших навика (пушење дувана, конзумирање алкохо-
ла и злоупотреба дрога) и података о постојању било којег 
оралног симптома и/или знака који се односи на патологију 
меких ткива усне дупље. Сви учесници били су подвргнути 
циљаним клиничким прегледима.
Резултати Сви болесници из студијске групе примали су 
психотропне лекове (средња вредност 4,18 ± 1,14, од јед-
ног до седам лекова). Болесници студијске групе имали су 
укупно 272 оралнa симптома и 121 знак оралних обољења, 
што је скоро четири пута више за оралне симптоме, а чак и 
девет пута више за знаке оралних поремећаја него у кон-
тролној групи.
Закључак Схизофренија као ментални поремећај не ути-
че директно на стање оралног здравља ове групе пси-
хијатријских болесника, већ индиректно – смањујући им 
мотивацију и свест о значају оралног здравља, посебно у 
болничким условима.
Kључне речи: орални симптоми; орални знаци; схизофре-
нија; болничко лечењe
Процена симптома и знакова оралних мекоткивних поремећаја код 
хоспитализованих болесника са схизофренијом 
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